NCT00699166View on ClinicalTrials.gov

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

PHASE2CompletedINTERVENTIONAL

Enrollment

135

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions

Irritable Bowel Syndrome

Interventions

DRUG

DNK333

25 mg and 100 mg oral doses, each taken twice daily

Trial Locations (29)

15010

Beaver Falls

33021

Hollywood

35476

Northport

35801

Huntsville

36207

Anniston

37205

Nashville

37404

Chattanooga

38119

Memphis

40504

Lexington

45440

Dayton

46260

Indianapolis

63090

Washington

65265

Mexico

67005

Arkansas City

68503

Lincoln

72117

North Little Rock

73104

Oklahoma City

74135

Tulsa

77566

Lake Jackson

78758

Austin

84102

Salt Lake City

85712

Tucson

90505

Torrance

92108

San Diego

92506

Riverside

92869

Orange

06010

Bristol

06106

Hartford

02215

Boston

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY

NCT00699166 - Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) | Biotech Hunter | Biotech Hunter